S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NYSE:UNH

UnitedHealth Group Competitors

$347.55
-7.45 (-2.10 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$347.54
Now: $347.55
$354.62
50-Day Range
$335.01
MA: $347.64
$365.03
52-Week Range
$187.72
Now: $347.55
$367.95
Volume2.59 million shs
Average Volume3.34 million shs
Market Capitalization$329.76 billion
P/E Ratio19.96
Dividend Yield1.41%
Beta0.74

Competitors

UnitedHealth Group (NYSE:UNH) Vs. JNJ, NVS, MRK, TMO, PFE, and ABT

Should you be buying UNH stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to UnitedHealth Group, including Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), Thermo Fisher Scientific (TMO), Pfizer (PFE), and Abbott Laboratories (ABT).

Johnson & Johnson (NYSE:JNJ) and UnitedHealth Group (NYSE:UNH) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.4%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and UnitedHealth Group has raised its dividend for 10 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation & Earnings

This table compares Johnson & Johnson and UnitedHealth Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.25$15.12 billion$8.6818.84
UnitedHealth Group$242.16 billion1.36$13.84 billion$15.1123.00

Johnson & Johnson has higher earnings, but lower revenue than UnitedHealth Group. Johnson & Johnson is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Johnson & Johnson and UnitedHealth Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
UnitedHealth Group6.62%27.53%9.40%

Institutional & Insider Ownership

67.3% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 86.0% of UnitedHealth Group shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.8% of UnitedHealth Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, UnitedHealth Group has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Johnson & Johnson and UnitedHealth Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031002.77
UnitedHealth Group051512.81

Johnson & Johnson presently has a consensus target price of $166.6923, suggesting a potential upside of 1.92%. UnitedHealth Group has a consensus target price of $387.8182, suggesting a potential upside of 11.59%. Given UnitedHealth Group's stronger consensus rating and higher possible upside, analysts plainly believe UnitedHealth Group is more favorable than Johnson & Johnson.

Summary

UnitedHealth Group beats Johnson & Johnson on 10 of the 18 factors compared between the two stocks.

Novartis (NYSE:NVS) and UnitedHealth Group (NYSE:UNH) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Dividends

Novartis pays an annual dividend of $2.01 per share and has a dividend yield of 2.1%. UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.4%. Novartis pays out 38.4% of its earnings in the form of a dividend. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UnitedHealth Group has raised its dividend for 10 consecutive years.

Valuation and Earnings

This table compares Novartis and UnitedHealth Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.50 billion4.67$11.73 billion$5.2418.49
UnitedHealth Group$242.16 billion1.36$13.84 billion$15.1123.00

UnitedHealth Group has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novartis and UnitedHealth Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis14.71%24.39%10.59%
UnitedHealth Group6.62%27.53%9.40%

Institutional & Insider Ownership

9.9% of Novartis shares are held by institutional investors. Comparatively, 86.0% of UnitedHealth Group shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.8% of UnitedHealth Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Novartis has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, UnitedHealth Group has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Novartis and UnitedHealth Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis22602.40
UnitedHealth Group051512.81

Novartis presently has a consensus target price of $114.00, suggesting a potential upside of 17.65%. UnitedHealth Group has a consensus target price of $387.8182, suggesting a potential upside of 11.59%. Given Novartis' higher possible upside, equities analysts clearly believe Novartis is more favorable than UnitedHealth Group.

Summary

UnitedHealth Group beats Novartis on 12 of the 18 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and UnitedHealth Group (NYSE:UNH) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.4%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 1 consecutive years and UnitedHealth Group has raised its dividend for 10 consecutive years.

Valuation and Earnings

This table compares Merck & Co., Inc. and UnitedHealth Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.37$9.84 billion$5.1915.60
UnitedHealth Group$242.16 billion1.36$13.84 billion$15.1123.00

UnitedHealth Group has higher revenue and earnings than Merck & Co., Inc.. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and UnitedHealth Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
UnitedHealth Group6.62%27.53%9.40%

Institutional & Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 86.0% of UnitedHealth Group shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.8% of UnitedHealth Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, UnitedHealth Group has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Merck & Co., Inc. and UnitedHealth Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021202.86
UnitedHealth Group051512.81

Merck & Co., Inc. presently has a consensus target price of $95.3571, suggesting a potential upside of 17.75%. UnitedHealth Group has a consensus target price of $387.8182, suggesting a potential upside of 11.59%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than UnitedHealth Group.

Summary

UnitedHealth Group beats Merck & Co., Inc. on 11 of the 18 factors compared between the two stocks.

Thermo Fisher Scientific (NYSE:TMO) and UnitedHealth Group (NYSE:UNH) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Dividends

Thermo Fisher Scientific pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.4%. Thermo Fisher Scientific pays out 7.1% of its earnings in the form of a dividend. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has raised its dividend for 3 consecutive years and UnitedHealth Group has raised its dividend for 10 consecutive years. UnitedHealth Group is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Thermo Fisher Scientific and UnitedHealth Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific041602.80
UnitedHealth Group051512.81

Thermo Fisher Scientific presently has a consensus target price of $492.8333, suggesting a potential downside of 4.23%. UnitedHealth Group has a consensus target price of $387.8182, suggesting a potential upside of 11.59%. Given UnitedHealth Group's stronger consensus rating and higher possible upside, analysts clearly believe UnitedHealth Group is more favorable than Thermo Fisher Scientific.

Institutional & Insider Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 86.0% of UnitedHealth Group shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 0.8% of UnitedHealth Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Thermo Fisher Scientific has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, UnitedHealth Group has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Valuation and Earnings

This table compares Thermo Fisher Scientific and UnitedHealth Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion7.99$3.70 billion$12.3541.67
UnitedHealth Group$242.16 billion1.36$13.84 billion$15.1123.00

UnitedHealth Group has higher revenue and earnings than Thermo Fisher Scientific. UnitedHealth Group is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Thermo Fisher Scientific and UnitedHealth Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
UnitedHealth Group6.62%27.53%9.40%

Summary

UnitedHealth Group beats Thermo Fisher Scientific on 10 of the 18 factors compared between the two stocks.

UnitedHealth Group (NYSE:UNH) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Dividends

UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.4%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UnitedHealth Group has increased its dividend for 10 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for UnitedHealth Group and Pfizer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UnitedHealth Group051512.81
Pfizer010402.29

UnitedHealth Group currently has a consensus price target of $387.8182, suggesting a potential upside of 11.59%. Pfizer has a consensus price target of $40.0714, suggesting a potential upside of 9.63%. Given UnitedHealth Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe UnitedHealth Group is more favorable than Pfizer.

Institutional & Insider Ownership

86.0% of UnitedHealth Group shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 0.8% of UnitedHealth Group shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

UnitedHealth Group has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Earnings and Valuation

This table compares UnitedHealth Group and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UnitedHealth Group$242.16 billion1.36$13.84 billion$15.1123.00
Pfizer$51.75 billion3.93$16.27 billion$2.9512.39

Pfizer has lower revenue, but higher earnings than UnitedHealth Group. Pfizer is trading at a lower price-to-earnings ratio than UnitedHealth Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares UnitedHealth Group and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UnitedHealth Group6.62%27.53%9.40%
Pfizer17.85%24.88%9.32%

Summary

UnitedHealth Group beats Pfizer on 13 of the 18 factors compared between the two stocks.

UnitedHealth Group (NYSE:UNH) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Dividends

UnitedHealth Group pays an annual dividend of $5.00 per share and has a dividend yield of 1.4%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.6%. UnitedHealth Group pays out 33.1% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UnitedHealth Group has increased its dividend for 10 consecutive years and Abbott Laboratories has increased its dividend for 49 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for UnitedHealth Group and Abbott Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UnitedHealth Group051512.81
Abbott Laboratories121302.75

UnitedHealth Group currently has a consensus price target of $387.8182, suggesting a potential upside of 11.59%. Abbott Laboratories has a consensus price target of $115.6875, suggesting a potential upside of 2.52%. Given UnitedHealth Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe UnitedHealth Group is more favorable than Abbott Laboratories.

Institutional & Insider Ownership

86.0% of UnitedHealth Group shares are owned by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are owned by institutional investors. 0.8% of UnitedHealth Group shares are owned by insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

UnitedHealth Group has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares UnitedHealth Group and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UnitedHealth Group$242.16 billion1.36$13.84 billion$15.1123.00
Abbott Laboratories$31.90 billion6.27$3.69 billion$3.2434.83

UnitedHealth Group has higher revenue and earnings than Abbott Laboratories. UnitedHealth Group is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares UnitedHealth Group and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UnitedHealth Group6.62%27.53%9.40%
Abbott Laboratories10.50%18.19%8.29%

Summary

UnitedHealth Group beats Abbott Laboratories on 11 of the 18 factors compared between the two stocks.


UnitedHealth Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.3$163.55-1.1%$430.55 billion$82.06 billion25.72Upcoming Earnings
News Coverage
Novartis logo
NVS
Novartis
2.0$96.90-0.0%$221.78 billion$47.50 billion31.36Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$80.98-0.2%$204.88 billion$46.84 billion17.92
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.0$514.60-0.4%$203.95 billion$25.54 billion42.18
Pfizer logo
PFE
Pfizer
2.7$36.55-0.2%$203.16 billion$51.75 billion23.58Analyst Report
Analyst Revision
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$112.84-0.1%$199.99 billion$31.90 billion59.70Upcoming Earnings
Eli Lilly and logo
LLY
Eli Lilly and
1.9$206.14-1.8%$197.19 billion$22.32 billion33.68Upcoming Earnings
Analyst Upgrade
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$110.86-0.4%$195.72 billion$33.27 billion23.44Analyst Revision
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.4$72.83-0.4%$171.50 billion$18.30 billion27.38Analyst Downgrade
Analyst Revision
Medtronic logo
MDT
Medtronic
2.7$116.58-1.1%$156.92 billion$28.91 billion44.50News Coverage
Amgen logo
AMGN
Amgen
2.3$253.50-0.6%$147.58 billion$23.36 billion20.44Analyst Report
Analyst Revision
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$64.56-0.6%$146.08 billion$26.15 billion-586.86
AZN
AstraZeneca
2.2$53.25-1.3%$139.76 billion$24.38 billion55.47Analyst Report
Analyst Revision
SNY
Sanofi
1.9$49.69-0.1%$124.43 billion$40.00 billion21.24Analyst Report
Analyst Revision
News Coverage
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.4$38.36-1.5%$96.23 billion$43.10 billion11.80Analyst Report
Analyst Revision
News Coverage
Stryker logo
SYK
Stryker
2.0$239.93-1.5%$90.16 billion$14.88 billion52.05Upcoming Earnings
News Coverage
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$744.08-7.3%$87.47 billion$4.48 billion84.75Earnings Announcement
Analyst Report
News Coverage
Gap Down
Gilead Sciences logo
GILD
Gilead Sciences
2.7$66.94-0.1%$83.91 billion$22.45 billion69.01Analyst Upgrade
Analyst Revision
News Coverage
Anthem logo
ANTM
Anthem
2.6$314.09-2.4%$78.12 billion$104.21 billion16.24Upcoming Earnings
Gap Down
Zoetis logo
ZTS
Zoetis
1.8$163.33-0.7%$77.63 billion$6.26 billion48.47Ex-Dividend
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$258.75-1.2%$75.26 billion$17.12 billion94.78
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$237.59-0.4%$61.78 billion$4.16 billion30.00Analyst Report
Analyst Revision
News Coverage
Illumina logo
ILMN
Illumina
1.5$406.25-0.3%$59.31 billion$3.54 billion94.26Insider Selling
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.4$537.78-0.4%$57.38 billion$7.86 billion19.66Analyst Report
TAK
Takeda Pharmaceutical
2.0$18.13-4.6%$57.16 billion$30.20 billion60.44Unusual Options Activity
News Coverage
Gap Up
HCA Healthcare logo
HCA
HCA Healthcare
2.1$166.97-0.3%$56.50 billion$51.34 billion16.88News Coverage
Humana logo
HUM
Humana
2.5$405.18-2.3%$53.62 billion$64.89 billion12.99Gap Down
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.52-2.0%$53.30 billion$4.35 billion68.42Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$37.03-1.3%$53.02 billion$10.74 billion14.19News Coverage
MRNA
Moderna
1.6$131.02-1.5%$51.85 billion$60.21 million-80.88Analyst Report
Insider Selling
Align Technology logo
ALGN
Align Technology
1.9$534.08-1.8%$42.11 billion$2.41 billion24.30Unusual Options Activity
News Coverage
Gap Down
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$492.86-0.7%$42.04 billion$2.41 billion85.86
Biogen logo
BIIB
Biogen
2.1$269.44-0.3%$41.46 billion$14.38 billion8.92Analyst Report
Analyst Revision
Baxter International logo
BAX
Baxter International
2.3$79.51-0.6%$40.62 billion$11.36 billion45.18
Teladoc Health logo
TDOC
Teladoc Health
1.3$263.00-6.7%$38.12 billion$553.31 million-183.92Insider Selling
News Coverage
Gap Up
ALC
Alcon
1.4$74.03-1.0%$36.14 billion$7.51 billion-50.36Analyst Report
Centene logo
CNC
Centene
2.3$61.51-2.0%$35.66 billion$74.64 billion17.13Analyst Report
DexCom logo
DXCM
DexCom
1.9$370.12-0.7%$35.54 billion$1.48 billion152.94
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.8$159.73-1.2%$34.96 billion$4.99 billion37.32Analyst Revision
News Coverage
BeiGene logo
BGNE
BeiGene
1.3$374.50-4.7%$34.15 billion$428.21 million-18.53Analyst Report
Insider Selling
Gap Up
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$161.01-1.2%$33.37 billion$7.98 billion1,006.38
Seagen logo
SGEN
Seagen
1.1$182.75-1.7%$33.06 billion$916.71 million71.95Analyst Report
ResMed logo
RMD
ResMed
1.4$215.52-0.7%$31.23 billion$2.96 billion46.25Upcoming Earnings
Insider Selling
McKesson logo
MCK
McKesson
2.2$185.01-1.2%$29.71 billion$231.05 billion14.08Insider Selling
News Coverage
GMAB
Genmab A/S
1.2$43.06-0.0%$28.22 billion$804.57 million33.38Analyst Downgrade
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.6$42.25-1.0%$24.74 billion$19.58 billion16.77
BNTX
BioNTech
1.1$108.44-2.8%$24.54 billion$121.63 million-54.22Gap Up
Cerner logo
CERN
Cerner
2.2$79.90-0.4%$24.50 billion$5.69 billion31.21Analyst Downgrade
News Coverage
Exact Sciences logo
EXAS
Exact Sciences
1.6$150.00-1.3%$22.56 billion$876.29 million-67.87Analyst Report
Analyst Revision
Gap Up
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$228.90-0.2%$22.29 billion$11.55 billion26.65Analyst Revision
This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.